
Treatment “holidays” to overcome resistance in advanced melanoma?
WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presente
WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presented at the American Association for Cancer Research 2013 meeting. Dr Darrin Stuart from the Novartis Institutes for Biomedical Research in Emeryville, California, presented research findings on mice treated with vemurafenib. He told Peter Goodwin why he thought this should prompt clinicians to look carefully at drug scheduling and consider intermittent therapy as a means of overcoming resistance in patients with cancer.
Next in AACR 2013
All 5 interviewsInterview 3 of 5

Gene expression and molecular pathways guide head and neck cancer therapies
WASHINGTON DC—Gene expression and molecular pathways in head and neck cancer have been identified with reference to The Cancer Genome Atlas in research presented at the American Association for Cancer
Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca